Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Approval symbols : Biib save search
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
Published: 2024-02-12 (Crawled : 21:00) - globenewswire.com
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: -3.72%
H: 0.58%
C: -3.82%
skyclarys first approval treat therapy
FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Published: 2023-07-07 (Crawled : 00:00) - prnewswire.com
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: 0.21%
H: 0.34%
C: -3.68%
leqembi fda disease approval treatment alzheimer's grants
Alcyone Therapeutics Receives FDA IDE Approval to Initiate Clinical Study of the ThecaFlex DRxTM System for Administration of SPINRAZA® (nusinersen)
Published: 2023-06-27 (Crawled : 12:00) - biospace.com/
IONS | $41.85 1.9% 1.86% 630K
|
Health Technology
|
| O: 0.08%
H: 1.3%
C: 0.59%
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: 0.12%
H: 0.56%
C: 0.37%
spinraza fda approval system therapeutics study
AI Proteins Announces the Formation of a Scientific Advisory Board Made up of Experts in Biotech and FDA Drug Approval
Published: 2023-05-31 (Crawled : 17:00) - biospace.com/
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: 0.0%
H: 0.3%
C: -0.76%
fda drug biotech approval
Muscular Dystrophy Association Celebrates FDA Approval of Biogen’s Qalsody for Treatment of SOD1-ALS
Published: 2023-04-25 (Crawled : 21:00) - biospace.com/
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: -0.68%
H: 1.01%
C: -2.97%
fda association approval treatment
FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS
Published: 2023-04-25 (Crawled : 20:00) - globenewswire.com
IONS | $41.85 1.9% 1.86% 630K
|
Health Technology
|
| O: 0.03%
H: 0.77%
C: -0.39%
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: -1.35%
H: 3.82%
C: 3.39%
fda genetic als approval treatment grants
Global Biosimilars Business and Investment Opportunities 2023: Attractive Approval Numbers Present Fertile Ground for New Entrants
Published: 2023-04-18 (Crawled : 18:00) - prnewswire.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.17%
H: 0.34%
C: -0.83%
CHRS | $2.19 0.46% 0.46% 810K
|
Health Technology
|
| O: 0.73%
H: 0.0%
C: -1.45%
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: 0.05%
H: 0.77%
C: 0.5%
business approval global
FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
Published: 2023-03-05 (Crawled : 00:00) - globenewswire.com
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: 0.09%
H: 0.79%
C: -0.09%
treatment fda disease application grants license approval alzheimer’s review
Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Published: 2023-01-07 (Crawled : 08:20) - prnewswire.com
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
| Email alert
Add to watchlist
treatment fda disease alzheimer's application license approval
FDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease
Published: 2023-01-06 (Crawled : 20:00) - prnewswire.com
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
| Email alert
Add to watchlist
treatment fda disease alzheimer's approval lecanemab leqembi
Neurologic Disorders Therapeutics Market Size to Grow by USD 33.46 billion, Approval Of Novel Drugs to Boost Market Growth - Technavio
Published: 2022-08-03 (Crawled : 04:00) - prnewswire.com
GLAXF | News | $20.305 -14.18% 630
|
Health Technology
|
| O: -1.8%
H: 0.2%
C: 0.0%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.6%
H: 0.0%
C: -0.76%
NPCE | $14.01 0.07% 0.07% 150K
|
Manufacturing
|
| O: 0.52%
H: 3.71%
C: -2.93%
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: 0.11%
H: 0.31%
C: -0.34%
GSK | News | $41.24 1.6% 0.0% 2.3M
|
Health Technology
|
| O: -0.29%
H: 0.24%
C: -0.58%
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.32%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.17%
H: 0.12%
C: -1.29%
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: 0.41%
H: 3.35%
C: 1.71%
ACAD | News | $16.735 -1.5% -1.52% 1.5M
|
Health Technology
|
| O: 2.47%
H: 2.8%
C: -2.67%
approval therapeutics growth market
THE U.S. FDA ACCEPTS AND GRANTS PRIORITY REVIEW FOR EISAI'S BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY
Published: 2022-07-05 (Crawled : 00:00) - prnewswire.com
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: 1.98%
H: 1.73%
C: 1.35%
fda disease alzheimer's application grants license approval review lecanemab
EISAI COMPLETES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY
Published: 2022-05-09 (Crawled : 00:00) - prnewswire.com
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: 0.94%
H: 0.0%
C: 0.0%
fda disease alzheimer's application license approval submission alzheimer’s lecanemab
EISAI INITIATES SUBMISSION OF APPLICATION DATA UNDER THE PRIOR ASSESSMENT CONSULTATION SYSTEM IN JAPAN WITH THE AIM OF OBTAINING EARLY APPROVAL FOR INVESTIGATIONAL ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY LECANEMAB
Published: 2022-03-03 (Crawled : 00:00) - prnewswire.com
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: -2.32%
H: 0.0%
C: 0.0%
ema application approval system antibody submission lecanemab anti-amyloid beta
Eisai Initiates Rolling Submission To The U.S. FDA For Biologics License Application Of Lecanemab (BAN2401) For Early Alzheimer's Disease Under The Accelerated Approval Pathway
Published: 2021-09-28 (Crawled : 06:00) - biospace.com/
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: 1.47%
H: 0.25%
C: -2.1%
disease alzheimer fda license approval submission alzheimer’s alzheimer's disease alzheimer's lecanemab
Eisai Initiates Rolling Submission To The U.S. FDA For Biologics License Application Of Lecanemab (BAN2401) For Early Alzheimer's Disease Under The Accelerated Approval Pathway
Published: 2021-09-27 (Crawled : 00:00) - prnewswire.com
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: 1.47%
H: 0.25%
C: -2.1%
disease alzheimer fda license approval submission alzheimer’s alzheimer's disease alzheimer's lecanemab
Global $21.2 Bn Advanced Therapy Medicinal Products Market to 2028: Breakthrough Approvals of Tecartus and Abecma Post-approval of Zolgensma, Kymriah, and Yescarta have Bolstered Rapid Advancements
Published: 2021-09-23 (Crawled : 12:00) - prnewswire.com
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: 0.92%
H: 0.5%
C: 0.01%
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: 0.42%
H: 1.55%
C: 0.38%
VCEL | $46.38 2.2% 2.16% 360K
|
Health Technology
|
| O: 0.86%
H: 2.12%
C: 1.89%
QURE | $4.755 -1.35% -1.37% 460K
|
Health Technology
|
| O: 0.5%
H: 0.58%
C: -5.62%
BLUE | $0.9739 2.13% 2.08% 4.8M
|
Health Technology
|
| O: 1.11%
H: 2.8%
C: 2.53%
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: 1.51%
H: 2.09%
C: -0.17%
therapy approval
CHMP Recommends VUMERITY® (diroximel fumarate) for Approval in the European Union as a Treatment for Relapsing-Remitting Multiple Sclerosis
Published: 2021-09-17 (Crawled : 14:00) - globenewswire.com
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: 0.24%
H: 0.0%
C: 0.0%
multiple sclerosis treatment europe sclerosis approval chmp
FDA grants accelerated approval for ADUHELM™ as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease
Published: 2021-06-07 (Crawled : 18:00) - globenewswire.com
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: 3.22%
H: 58.64%
C: 34.03%
disease alzheimer treatment fda approval alzheimer’s alzheimer's disease alzheimer's
Biogen Grows Presence in China with the Approval of TECFIDERA® (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis
Published: 2021-04-15 (Crawled : 21:00) - globenewswire.com
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: 0.06%
H: 1.19%
C: -0.11%
multiple sclerosis treatment china sclerosis approval
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.